We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Evaluation the Diagnostic Ability of the Cancer Detection Technology (CDT) to Detect Breast Cancer Among Women Population Over Age 40

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01043055
Recruitment Status : Unknown
Verified October 2009 by Hadassah Medical Organization.
Recruitment status was:  Not yet recruiting
First Posted : January 6, 2010
Last Update Posted : January 6, 2010
Information provided by:
Hadassah Medical Organization

Brief Summary:
This study aimed to validate the diagnostic ability of the CDT (cancer detection technology) software to detect breast cancer among women population.

Condition or disease
Breast Cancer

Detailed Description:

Breast cancer diagnosis is a rapidly expanding research field, whose early-stage detection may reduce the burden of the disease and permit more effective treatment. It is well documented that tumor growth requires specific conditions for its development from the occurrence of a mutation to a clinically detectable cancer. It has been shown that living peripheral blood mononuclear cells (PBMC) have different ability of cytosolic enzymes (esterases) to convert hydrophobic substrate fluorescein diacetate (FDA) into hydrophilic fluorescent fluorescein. It depends on PBMC cycle stage, size, surface state, physiological states, such as activation and apoptosis.

The important step of breast cancer genesis is the early change of functional activity of cytosolic enzymes (esterases) in peripheral blood mononuclear cells. Such transformations in PBMC may be detected accurately by an existing device Flowcytometer (FACS™ MultiSET™ System, company "Becton Dickinson" GmbH, USA), where measurements of fluorescence polarization and enzymatic hydrolysis of FDA substrate are recorded. A conclusion about presentation of breast cancer among examined women is achieved by "CDT" (cancer detection technology) software, which analyzes mathematically the results of fluorescence polarization and enzymatic hydrolysis.

Moreover, the combined biochemical model together with additional prognostic parameters (such as age, ethnic group, gynecological and obstetric anamnesis) increases the validity (accuracy, sensitivity and specificity) of the diagnostic conclusion.

Diagnostic Solution of the CDT:

  1. Mathematical processing of specific blood analysis in device Flowcytometer.
  2. Mathematical evaluation of specific prognostic parameters

Study Type : Observational
Estimated Enrollment : 140 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation the Diagnostic Ability of the CDT to Detect Breast Cancer Among Women Population Over Age 40
Study Start Date : January 2010
Estimated Primary Completion Date : January 2010
Estimated Study Completion Date : January 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
U.S. FDA Resources

Breast Cancer Patients
Healthy Control Group

Primary Outcome Measures :
  1. To validate the diagnostic ability of the CDT to detect breast cancer among women population over age 40 [ Time Frame: one year ]

Secondary Outcome Measures :
  1. To correlate the technology with standard test - screening mammography and biopsy [ Time Frame: two years ]
  2. To validate and compare the diagnostic ability of the CDT for detection of breast cancer [ Time Frame: two years ]

Biospecimen Retention:   Samples Without DNA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Breast cancer patients over age 40 before treatment. Healthy women recruited in Check Up institute from asymptomatic women over age 40, referred to screening mammography and received the negative result of mammography.

Inclusion Criteria:

Inclusion Criteria for Breast Cancer Patients for Experimental Group:

  1. Patient is over the age of 40.
  2. Patient is willing to participate as evidenced by signing the written informed consent form.
  3. Patient referred to the Department of Oncology/ Surgery for operative treatment of breast cancer with previously detected disease. Positive conventional tests finding can include (but not limited to) the record of screening or diagnostic mammography, blood oncomarkers, breast ultrasound, breast CT, biopsy.
  4. Non-treated patients (w/o previous chemotherapy, hormonal drugs and radiotherapy).
  5. Patient without other cancer locations

Inclusion Criteria for Presumably Healthy Subjects for Control Group:

  1. Subjects over the age of 40.
  2. Subjects who are willing to participate as evidenced by signing the written informed consent form.
  3. Subjects who are presumably healthy and without breast pathologies' symptoms and family history of breast cancer, i.e., breast disease (except history of functional breast problems, e.g., mastitis within lactation period) has been ruled out based on physician anamnesis
  4. Subjects with negative results of screening mammography.
  5. Subjects without taking of any hormonal medicines

Exclusion Criteria:

  1. Subjects with any known cancer in other internal organs or systems.
  2. Subjects with high fever presentation (more than 38.5).
  3. Subjects with known breast disease undergoing treatment for the disease.
  4. Pregnant or lactating women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01043055

Contact: Tamar Peretz, MD 6777825 ext 009722 tamary@hadassah.org.il
Contact: Hadas Lemberg, PhD 6777572 ext 009722 lhadas@hadassah.org.il

Hadassah Medical Organization Not yet recruiting
Jerusalem, Israel, 91120
Contact: Arik Tzukert, DmD    6776095 ext 009722    arik@hadassah.org.il   
Contact: Hadas Lemberg, PhD    6777572 ext 009722    Lhadas@hadassah.org.il   
Sub-Investigator: Benjamin Nisman, PhD         
Sub-Investigator: Tamar Sella, MD         
Sub-Investigator: Tzeela Cohen, MD         
Sub-Investigator: Oded Zamir, MD         
Sponsors and Collaborators
Hadassah Medical Organization
Principal Investigator: Tamar Peretz, MD Hadassah Medical Organization

Responsible Party: Prof. Tamar Peretz, Head of Oncology Department, Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT01043055     History of Changes
Other Study ID Numbers: 044809-HMO-CTIL
First Posted: January 6, 2010    Key Record Dates
Last Update Posted: January 6, 2010
Last Verified: October 2009

Keywords provided by Hadassah Medical Organization:
Breast Cancer Screening

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases